Organogenesis (NASDAQ:ORGO – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The business had revenue of $45.46 million during the quarter, compared to the consensus estimate of $52.10 million.
Here are the key takeaways from Organogenesis’ conference call:
- Third-quarter net product revenue fell 70% year over year, though it rose 6% sequentially. The company lowered its 2026 revenue outlook to $179 million–$200 million and described the market recovery as more measured than previously expected.
- Organogenesis said it gained market share, with claims data indicating its share increased more than 30% versus Q1, and reported sequential sales growth across Advanced Wound Care and Surgical & Sports Medicine. Management believes the market has bottomed, while acknowledging that low-cost inventory and ongoing customer uncertainty may continue to affect recovery.
- The company reported a $29.6 million GAAP net loss and had $26.9 million in cash and restricted cash at quarter-end, down from $94.3 million at year-end 2025. Management expects further sequential improvement in adjusted EBITDA, but positive adjusted EBITDA in Q4 is anticipated only at the high end of its outlook.
- The FDA review of Amnuvx faces a longer timeline after the agency identified 18 items requiring remediation at the Norwood facility and requested additional clinical information. The company expects remediation to finish by September 2027, estimates an $8 million total cost, and said the PDUFA target date will be extended from April 2027.
Organogenesis Stock Performance
ORGO traded up $0.05 on Friday, hitting $0.89. The company’s stock had a trading volume of 353,428 shares, compared to its average volume of 1,004,104. Organogenesis has a 12 month low of $0.73 and a 12 month high of $7.08. The firm has a market cap of $114.40 million, a P/E ratio of -1.03 and a beta of 1.48. The company has a quick ratio of 3.00, a current ratio of 3.52 and a debt-to-equity ratio of 0.07. The company’s 50 day simple moving average is $1.28 and its 200-day simple moving average is $2.32.
Analysts Set New Price Targets
A number of research analysts have issued reports on ORGO shares. Weiss Ratings lowered shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Wall Street Zen upgraded shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Truist Financial decreased their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $4.33.
Organogenesis Company Profile
Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.
Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.
Read More
- Five stocks we like better than Organogenesis
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
